FDA Informs Sarepta That It Recommends That Sarepta Remove Its Pause and Resume Shipments of ELEVIDYS for Ambulatory Individuals With Duchenne Muscular Dystrophy – Sarepta Therapeutics

1. FDA Informs Sarepta That It Recommends That Sarepta Remove Its Pause and Resume Shipments of ELEVIDYS for Ambulatory Individuals With Duchenne Muscular Dystrophy  Sarepta Therapeutics
2. Updated: Sarepta would have to conduct new studies to get back on market, FDA official says  Endpoints News
3. FDA permits use of Sarepta Therapeutics’ Duchenne therapy in younger patients after short-lived halt  statnews.com
4. The deadly saga of the controversial gene therapy Elevidys  MIT Technology Review
5. Third patient dies after receiving a Sarepta gene therapy  Progress Educational Trust

Continue Reading